Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.03.2021 | Case report

Infliximab

Lack of drug effect: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Bryant K, et al. Biosimilar brand switch associated with loss of efficacy in psoriasis repaired by return to originator brand. British Journal of Dermatology 183 (Suppl.): 75-76 (plus poster) abstr. P105, Sep 2020. Available from: URL: http://doi.org/10.1111/bjd.18968 [abstract] Bryant K, et al. Biosimilar brand switch associated with loss of efficacy in psoriasis repaired by return to originator brand. British Journal of Dermatology 183 (Suppl.): 75-76 (plus poster) abstr. P105, Sep 2020. Available from: URL: http://​doi.​org/​10.​1111/​bjd.​18968 [abstract]
Metadaten
Titel
Infliximab
Lack of drug effect: case report
Publikationsdatum
01.03.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-92095-x

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Multiple drugs

Case report

Telbivudine

Case report

Adalimumab

Case report

Adalimumab

Case report

Multiple drugs